EpiCast Report: Acute Coronary Syndrome – Epidemiology Forecast to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences and hospitalizations, and high risks of sudden death and short-term mortality. The ACS incidence increases with age and will be a significant public health problem as the elderly population increases around the world. ACS is classified into three disease entities based on evidence of heart muscle damage inferred from a person's symptoms, changes in the ST tracing of the electrocardiogram (ECG), and levels of cardiac biomarkers that signify heart muscle death: ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA). These three disease entities differ in their clinical characteristics, treatment approaches, and survival probabilities.

GlobalData epidemiologists forecast that in the 7MM, the diagnosed prevalent cases of ACS will grow from 25.45 million cases in 2015 to 30.62 million cases in 2025, at an Annual Growth Rate (AGR) of 2.03%. Throughout the forecast period, the diagnosed prevalent cases of ACS in the US will constitute the highest proportion in the 7MM at approximately 54%. In the 7MM, the diagnosed prevalent cases of ACS will be higher in men (61.81%) and in the age group older than 65 years (62.84%). STEMI, NSTEMI, and UA will constitute approximately 25%, 40%, and 35% of the diagnosed prevalent cases of ACS in the 7MM. In the 7MM, GlobalData epidemiologists project ACS hospitalizations to increase from 1.63 million cases in 2015 to 1.71 million cases in 2025 at an AGR of 0.51%. The US constitutes around 40% of the total hospitalized ACS cases in the 7MM for the year 2015 and will be the market with the highest number of cases during the forecast period. In 2015, the majority of the ACS hospitalizations occurred in men (62.85%) and in the age group older than 65 years (69.34%). In the year 2015, about 29% of the ACS cases in the 7MM were STEMI, 44% were NSTEMI, and 25% were UA.

Scope

The Acute coronary syndrome (ACS) EpiCast Report and EpiCast Model provides an overview of the risk factors, comorbidities, and the global and historical trends for ACS in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast from 2015–2025 for the diagnosed prevalent cases of ACS, segmented by sex, age (in 10 year age groups from ages =25 years), and ACS type (STEMI, NSTEMI, and UA), and a 10-year epidemiological forecast for ACS hospitalizations, segmented by sex and ACS type (STEMI, NSTEMI, and UA).

The ACS epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Epidemiology

2.1Disease Background

2.2Risk Factors and Comorbidities

2.3Global Trends

2.3.1ACS Diagnosed Prevalence

2.3.2STEMI and NSTEMI Trends

2.3.3ACS Hospitalizations

2.4Forecast Methodology

2.4.1Sources Used

2.4.2Forecast Assumptions and Methods

2.4.3Sources Not Used

2.5Epidemiological Forecast for ACS (2015–2025)

2.5.1Diagnosed Prevalent Cases of ACS

2.5.2Age–Specific Diagnosed Prevalent Cases of ACS

2.5.3Sex-Specific Diagnosed Prevalent Cases of ACS

2.5.4Diagnosed Prevalent Cases of ACS Segmented by STEMI, NSTEMI, and UA

2.5.5Age-Standardized Diagnosed Prevalence of ACS

2.5.6ACS Hospitalizations

2.5.7Sex-Specific ACS Hospitalizations

2.5.8ACS Hospitalizations Segmented by STEMI, NSTEMI, and UA

2.6Discussion

2.6.1Epidemiological Forecast Insight

2.6.2Limitations of the Analysis

2.6.3Strengths of the Analysis

3Appendix

3.1Bibliography

3.2About the Authors

3.2.1Epidemiologists

3.2.2Reviewers

3.2.3Global Director of Therapy Analysis and Epidemiology

3.2.4Global Head of Healthcare

3.3About GlobalData

3.4About EpiCast

3.5Disclaimer

Table

Table 1: Risk Factors and Comorbidities for ACS

Table 2: Global, Crude Total Population Prevalence Percentages of Angina Pectoris and Mean Age of Study Participants

Table 3: 7MM, Sources of Diagnosed Prevalence Data for MI

Table 4: 7MM, Data Sources of STEMI and NSTEMI Proportions Among Diagnosed Prevalent Cases of MI

Table 5: 7MM, Data Sources of ACS Hospitalizations

Table 6: 7MM, Data Sources of STEMI and NSTEMI Proportions Among MI Hospitalizations

Table 7: 7MM, Diagnosed Prevalent Cases of ACS, Ages =25 Years, Both Sexes, N, Select Years, 2015–2025

Table 8: 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N (Row %), 2015

Table 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages =25 Years, N (Row %), 2015

Table 10: 7MM, Diagnosed Prevalent Cases of STEMI, NSTEMI, and UA, Ages =25 Years, N (Row %), 2015

Table 11: 7MM ACS Hospitalizations, Ages =25 Years, Both Sexes, N, Select Years, 2015–2025

Table 12: 7MM, Sex-Specific ACS Hospitalizations, Ages =25 Years, N (Row %), 2015

Table 13: 7MM, Diagnosed ACS Hospitalizations Segmented by STEMI, NSTEMI and UA, Ages =25 Years, Both Sexes, N, 2015

Figures

Figure 1: US, Germany, and UK, Crude Diagnosed MI Prevalence in Men and Women, 1990–2008

Figure 2: Global, Crude Total Population Prevalence Percentages of Angina Pectoris (%)

Figure 3: Case Segmentation Map

Figure 4: 7MM, Diagnosed Prevalent Cases of ACS, Ages =25 Years, Both Sexes, N, Select Years, 2015–2025

Figure 5; 7MM, Age-Specific Diagnosed Prevalent Cases of ACS, Men and Women, N, 2015

Figure 6: 7MM, Sex-Specific Diagnosed Prevalent Cases of ACS, Ages =25 Years, N, 2015

Figure 7: 7MM, Diagnosed Prevalent Cases of STEMI and NSTEMI, Ages =25 Years, N, 2015

Figure 8: 7MM, Age-Standardized Diagnosed Prevalence of ACS, Ages =25 Years, 2015

Figure 9: 7MM ACS Hospitalizations, Ages =25 Years, Both Sexes, N, Select Years, 2015–2025

Figure 10: 7MM, Sex-Specific ACS, Ages =25 Years, N, 2015

Figure 11: 7MM, Diagnosed ACS Hospitalizations Segmented by NSTEMI and STEMI, Ages =25 Years, Both Sexes, N, 2015

Frequently asked questions

EpiCast Report: Acute Coronary Syndrome – Epidemiology Forecast to 2025 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

EpiCast Report: Acute Coronary Syndrome – Epidemiology Forecast to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EpiCast Report: Acute Coronary Syndrome – Epidemiology Forecast to 2025 in real time.

  • Access a live EpiCast Report: Acute Coronary Syndrome – Epidemiology Forecast to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.